<VariationArchive VariationID="599216" VariationName="NM_001298.3(CNGA3):c.130_151dup (p.Ala51fs)" VariationType="Duplication" Accession="VCV000599216" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-06-23" DateCreated="2018-12-30" MostRecentSubmission="2020-02-16">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="590440" VariationID="599216">
      <GeneList>
        <Gene Symbol="CNGA3" FullName="cyclic nucleotide gated channel subunit alpha 3" GeneID="1261" HGNC_ID="HGNC:2150" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2q11.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="98346456" stop="98398601" display_start="98346456" display_stop="98398601" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="98962617" stop="99015063" display_start="98962617" display_stop="99015063" Strand="+" />
          </Location>
          <OMIM>600053</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_001298.3(CNGA3):c.130_151dup (p.Ala51fs)</Name>
      <CanonicalSPDI>NC_000002.12:98377710:ATCGTCAGTGCTGCAGCCGGGGATCG:ATCGTCAGTGCTGCAGCCGGGGATCGTCAGTGCTGCAGCCGGGGATCG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>2q11.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="98377710" stop="98377711" display_start="98377710" display_stop="98377711" variantLength="22" positionVCF="98377710" referenceAlleleVCF="C" alternateAlleleVCF="CATCGTCAGTGCTGCAGCCGGGG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="98994173" stop="98994174" display_start="98994173" display_stop="98994174" variantLength="22" positionVCF="98994173" referenceAlleleVCF="C" alternateAlleleVCF="CATCGTCAGTGCTGCAGCCGGGG" />
      </Location>
      <ProteinChange>A51fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.98994178_98994199dup" Assembly="GRCh37">
            <Expression>NC_000002.11:g.98994178_98994199dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.98377715_98377736dup" Assembly="GRCh38">
            <Expression>NC_000002.12:g.98377715_98377736dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009097.1" sequenceAccession="NG_009097" sequenceVersion="1" change="g.36561_36582dup">
            <Expression>NG_009097.1:g.36561_36582dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079878.2" sequenceAccession="NM_001079878" sequenceVersion="2" change="c.130_151dup">
            <Expression>NM_001079878.2:c.130_151dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073347.1" sequenceAccession="NP_001073347" sequenceVersion="1" change="p.Ala51fs">
            <Expression>NP_001073347.1:p.Ala51fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001298.3" sequenceAccession="NM_001298" sequenceVersion="3" change="c.130_151dup" MANESelect="true">
            <Expression>NM_001298.3:c.130_151dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001289.1" sequenceAccession="NP_001289" sequenceVersion="1" change="p.Ala51fs">
            <Expression>NP_001289.1:p.Ala51fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001298.2" sequenceAccession="NM_001298" sequenceVersion="2" change="c.130_151dup22">
            <Expression>NM_001298.2:c.130_151dup22</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1558811557" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="RNA degradation by nonsense-mediated decay">
        <XRef ID="0347" DB="Variation Ontology" />
      </FunctionalConsequence>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001298.3(CNGA3):c.130_151dup (p.Ala51fs) AND Achromatopsia 2" Accession="RCV000735808" Version="2">
        <ClassifiedConditionList TraitSetID="6436">
          <ClassifiedCondition DB="MedGen" ID="C1857618">Achromatopsia 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-09-26" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_001298.3(CNGA3):c.130_151dup (p.Ala51fs) AND Achromatopsia" Accession="RCV001002959" Version="1">
        <ClassifiedConditionList TraitSetID="10198">
          <ClassifiedCondition DB="MedGen" ID="C0152200">Achromatopsia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2019-06-23" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-09-26" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2018-12-30" MostRecentSubmission="2020-02-16">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Likely pathogenic</Description>
        <ConditionList>
          <TraitSet ID="10198" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="9454" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Rod monochromatism</ElementValue>
                <XRef ID="HP:0011516" DB="Human Phenotype Ontology" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Achromatopsia</ElementValue>
                <XRef ID="2668" DB="GeneTests" />
                <XRef ID="Achromatopsia/9534" DB="Genetic Alliance" />
                <XRef ID="HP:0011516" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0018852" DB="MONDO" />
                <XRef ID="56852002" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Achromatopsia is characterized by reduced visual acuity, pendular nystagmus, increased sensitivity to light (photophobia), a small central scotoma, eccentric fixation, and reduced or complete loss of color discrimination. All individuals with achromatopsia (achromats) have impaired color discrimination along all three axes of color vision corresponding to the three cone classes: the protan or long-wavelength-sensitive cone axis (red), the deutan or middle-wavelength-sensitive cone axis (green), and the tritan or short-wavelength-sensitive cone axis (blue). Most individuals have complete achromatopsia, with total lack of function of all three types of cones. Rarely, individuals have incomplete achromatopsia, in which one or more cone types may be partially functioning. The manifestations are similar to those of individuals with complete achromatopsia, but generally less severe. Hyperopia is common in achromatopsia. Nystagmus develops during the first few weeks after birth followed by increased sensitivity to bright light. Best visual acuity varies with severity of the disease; it is 20/200 or less in complete achromatopsia and may be as high as 20/80 in incomplete achromatopsia. Visual acuity is usually stable over time; both nystagmus and sensitivity to bright light may improve slightly. Although the fundus is usually normal, macular changes (which may show early signs of progression) and vessel narrowing may be present in some affected individuals. Defects in the macula are visible on optical coherence tomography.</Attribute>
                <XRef ID="NBK1418" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15015" />
                <XRef ID="15015" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301591</ID>
                <ID Source="BookShelf">NBK1418</ID>
              </Citation>
              <XRef ID="49382" DB="Orphanet" />
              <XRef ID="C0152200" DB="MedGen" />
              <XRef ID="MONDO:0018852" DB="MONDO" />
              <XRef Type="primary" ID="HP:0011516" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6436" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="171" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Achromatopsia 2</ElementValue>
                <XRef ID="Achromatopsia+2/116" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009003" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Colorblindness, total</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rod monochromatism 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rod monochromacy 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">ACHM2</ElementValue>
                <XRef Type="MIM" ID="216900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RMCH2</ElementValue>
                <XRef Type="MIM" ID="216900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CNGA3</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Achromatopsia is characterized by reduced visual acuity, pendular nystagmus, increased sensitivity to light (photophobia), a small central scotoma, eccentric fixation, and reduced or complete loss of color discrimination. All individuals with achromatopsia (achromats) have impaired color discrimination along all three axes of color vision corresponding to the three cone classes: the protan or long-wavelength-sensitive cone axis (red), the deutan or middle-wavelength-sensitive cone axis (green), and the tritan or short-wavelength-sensitive cone axis (blue). Most individuals have complete achromatopsia, with total lack of function of all three types of cones. Rarely, individuals have incomplete achromatopsia, in which one or more cone types may be partially functioning. The manifestations are similar to those of individuals with complete achromatopsia, but generally less severe. Hyperopia is common in achromatopsia. Nystagmus develops during the first few weeks after birth followed by increased sensitivity to bright light. Best visual acuity varies with severity of the disease; it is 20/200 or less in complete achromatopsia and may be as high as 20/80 in incomplete achromatopsia. Visual acuity is usually stable over time; both nystagmus and sensitivity to bright light may improve slightly. Although the fundus is usually normal, macular changes (which may show early signs of progression) and vessel narrowing may be present in some affected individuals. Defects in the macula are visible on optical coherence tomography.</Attribute>
                <XRef ID="NBK1418" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9649" />
                <XRef ID="9649" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301591</ID>
                <ID Source="BookShelf">NBK1418</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="pmc">3110037</ID>
              </Citation>
              <XRef ID="49382" DB="Orphanet" />
              <XRef ID="C1857618" DB="MedGen" />
              <XRef ID="MONDO:0009003" DB="MONDO" />
              <XRef Type="MIM" ID="216900" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1689593" SubmissionDate="2018-12-20" DateLastUpdated="2018-12-30" DateCreated="2018-12-30">
        <ClinVarSubmissionID localKey="SUB4802060" submittedAssembly="GRCh37" title="SUB4802060" />
        <ClinVarAccession Accession="SCV000853079" DateUpdated="2018-12-30" DateCreated="2018-12-30" Type="SCV" Version="1" SubmitterName="Tehran Medical Genetics Laboratory" OrgID="506617" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-09-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The c.130_151dup p.(Ala51Valfs*16) creates a shift in the reading frame starting at codon 51. The new reading frame ends in a stop codon 15 positions downstream. This variant has been confirmed by Sanger sequencing and it is classified as likely pathogenic (class 2) according to the recommendations of Centogene and ACMG.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Iranian</Ethnicity>
              <GeographicOrigin>Middle East</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <NamePlatform>Illumina</NamePlatform>
              <TypePlatform>Next-generation sequencing</TypePlatform>
              <Description>Genomic DNA is enzymatically fragmented and regions of interest are selectively enriched using capture probes targeted against coding regions of ~6700 genes with known clinical significance. Libraries are generated with Illumina compatible adaptors and sequenced on an Illumina platform. Evaluation is focused on coding exons along with flanking +/-10 intronic bases within the captured region. Due to limitations of the method, the target region is not covered 100%. Raw sequence data analysis, including base calling, multiplexing, alignment to the hg19 human reference genome (Genome Reference Consortium GRCh37) and variant calling, is performed using validated in-house software. Relevant variants reported in HGMDÂ®, in ClinVar or in CentoMDÂ® as well as all variants with minor allele frequency (MAF) of less than 1% in gnomAD database are considered. All pertinent inheritance patterns are considered. In addition, provided family history and clinical information are used to evaluate eventually identified variants. All identified variants are evaluated with respect to their pathogenicity and causality, and these are categorized in classes 1 - 5. All variants related to the phenotype of the patient, except benign or likely benign variants, are reported. Any relevant variant(s) identified by NGS is (are) Sanger sequenced to exclude NGS artifacts.</Description>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="TestName">CentoDXâ„¢</Attribute>
              </MethodAttribute>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory" dateValue="2018-09-24">Centogene</Attribute>
                <Comment>Likely pathogenic</Comment>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="1" />
            </ObservedData>
            <TraitSet DateLastEvaluated="2018-06-02" Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <Name>
                  <ElementValue Type="Preferred">nystagmus</ElementValue>
                </Name>
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <Name>
                  <ElementValue Type="Preferred">photophobia</ElementValue>
                </Name>
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <Name>
                  <ElementValue Type="Preferred">rod-cone dystrophy</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CNGA3">
              <Name>cyclic nucleotide gated channel alpha 3</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <FunctionalConsequence Value="RNA degradation by nonsense-mediated decay">
            <XRef DB="Variation Ontology" ID="0347" URL="http://purl.obolibrary.org/obo/VariO_0347" />
          </FunctionalConsequence>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001298.2:c.130_151dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="216900" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4802060</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2288298" SubmissionDate="2019-06-25" DateLastUpdated="2020-02-16" DateCreated="2020-02-16">
        <ClinVarSubmissionID localKey="NM_001298.2:c.130_151dup22|achromatopsia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001161002" DateUpdated="2020-02-16" DateCreated="2020-02-16" Type="SCV" Version="1" SubmitterName="Sharon lab, Hadassah-Hebrew University Medical Center" OrgID="506232" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-23">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
              <MethodAttribute>
                <Attribute Type="StructVarMethodType">Read depth</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CNGA3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001298.2:c.130_151dup22</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">achromatopsia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5871661</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1689593" TraitType="Disease" MappingType="XRef" MappingValue="216900" MappingRef="OMIM">
        <MedGen CUI="C1857618" Name="Achromatopsia 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288298" TraitType="Disease" MappingType="Name" MappingValue="achromatopsia" MappingRef="Preferred">
        <MedGen CUI="C0152200" Name="Achromatopsia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1689593" TraitType="Finding" MappingType="Name" MappingValue="photophobia" MappingRef="Preferred">
        <MedGen CUI="C0085636" Name="Photophobia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1689593" TraitType="Finding" MappingType="Name" MappingValue="rod-cone dystrophy" MappingRef="Preferred">
        <MedGen CUI="C4551714" Name="Rod-cone dystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1689593" TraitType="Finding" MappingType="Name" MappingValue="nystagmus" MappingRef="Preferred">
        <MedGen CUI="C0028738" Name="Nystagmus" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

